Free Trial

Bolt Biotherapeutics (BOLT) 10K Form and Latest SEC Filings 2026

Bolt Biotherapeutics logo
$4.82 -0.25 (-4.84%)
As of 03:53 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Latest Bolt Biotherapeutics SEC Filings & Recent Activity

Bolt Biotherapeutics (NASDAQ:BOLT) has submitted 156+ documents to the U.S. Securities and Exchange Commission (SEC) since 2018. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form DEFA14A submitted on April 28, 2026.

Form 4
Bolt Biotherapeutics, Inc. Reports Ownership Change on Feb. 4, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

10-Q
Bolt Biotherapeutics Files Quarterly Report on Nov. 12, 2025

The 10-Q contains Bolt Biotherapeutics's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Bolt Biotherapeutics SEC Filing History

Browse Bolt Biotherapeutics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
04/28/2026 3:05 PM
Bolt Biotherapeutics (1641281) Filer
Form DEF 14A
04/28/2026 3:06 PM
Bolt Biotherapeutics (1641281) Filer
Form DEFA14A
03/12/2026 3:14 PM
Bolt Biotherapeutics (1641281) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
02/26/2026 6:22 PM
Bolt Biotherapeutics (1641281) Subject
Pivotal bioVenture Partners Fund I, L.P. (1695076) Filed by
Form SCHEDULE 13D/A
02/17/2026 7:11 PM
Bolt Biotherapeutics (1641281) Subject
Pivotal bioVenture Partners Fund I, L.P. (1695076) Filed by
Form SCHEDULE 13D/A
02/13/2026 5:48 PM
Bolt Biotherapeutics (1641281) Subject
Vivo Panda Fund, L.P. (1675490) Filed by
Form SCHEDULE 13G/A
02/04/2026 3:32 PM
Bolt Biotherapeutics (1641281) Issuer
Nemec Sarah (2023538) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/04/2026 3:32 PM
Bolt Biotherapeutics (1641281) Issuer
Yonehiro Grant (1428666) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/04/2026 3:32 PM
Bolt Biotherapeutics (1641281) Issuer
Quinn William P. (1724190) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/16/2025 4:14 PM
Bolt Biotherapeutics (1641281) Issuer
ONETTO NICOLE (1220049) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/16/2025 4:15 PM
Bolt Biotherapeutics (1641281) Issuer
Dupont Jakob (1553335) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/16/2025 4:11 PM
Bolt Biotherapeutics (1641281) Issuer
Quinn William P. (1724190) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/16/2025 4:11 PM
Bolt Biotherapeutics (1641281) Issuer
Yonehiro Grant (1428666) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/16/2025 4:12 PM
Bolt Biotherapeutics (1641281) Issuer
Nemec Sarah (2023538) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/16/2025 4:13 PM
Bolt Biotherapeutics (1641281) Issuer
O'CALLAGHAN BRIAN (1415015) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/16/2025 4:13 PM
Bolt Biotherapeutics (1641281) Issuer
LAPORTE KATHLEEN (1196201) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/16/2025 4:14 PM
Berner Laura (1958382) Reporting
Bolt Biotherapeutics (1641281) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/12/2025 3:08 PM
Bolt Biotherapeutics (1641281) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/24/2025 6:18 PM
Bolt Biotherapeutics (1641281) Issuer
Quinn William P. (1724190) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/24/2025 6:18 PM
Bolt Biotherapeutics (1641281) Issuer
Yonehiro Grant (1428666) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/24/2025 6:19 PM
Bolt Biotherapeutics (1641281) Issuer
Nemec Sarah (2023538) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/14/2025 3:15 PM
Bolt Biotherapeutics (1641281) Subject
TANG CAPITAL MANAGEMENT LLC (1232621) Filed by
Form SCHEDULE 13G/A
08/14/2025 3:09 PM
Bolt Biotherapeutics (1641281) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
06/04/2025 3:05 PM
Bolt Biotherapeutics (1641281) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/05/2025 8:28 PM
Bolt Biotherapeutics (1641281) Issuer
Dupont Jakob (1553335) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/05/2025 7:35 PM
Bolt Biotherapeutics (1641281) Issuer
Quinn William P. (1724190) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/05/2025 7:40 PM
Bolt Biotherapeutics (1641281) Issuer
Nemec Sarah (2023538) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/05/2025 7:41 PM
Bolt Biotherapeutics (1641281) Issuer
Yonehiro Grant (1428666) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)

Bolt Biotherapeutics SEC Filings - Frequently Asked Questions

Bolt Biotherapeutics (BOLT) has submitted 156+ filings to the SEC since 2018. You can browse the complete history or filter by form type using the tools above.

Bolt Biotherapeutics's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results.

The most recent filing was a Form DEFA14A submitted on April 28, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:BOLT) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners